A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps

Trial Profile

A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Mepolizumab (Primary) ; Mometasone
  • Indications Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Acronyms SYNAPSE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jun 2017 According to a GlaxoSmithKline media release, results of this trial will inform any regulatory filing plans for mepolizumab for the treatment of nasal polyps.
    • 09 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 23 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top